FORMULATION ARTICLES
-
![AI Medical Technology-GettyImages-2242544252]( "Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design Framework")
Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design FrameworkNew backbone chemistries could unlock greater control over delivery, specificity, and safety, expanding the molecular design space for RNA medicines.
-
![Virology, infectious diseases, virus diagnostics, virus research, biotechnology-GettyImages-2219621039]( "RNA Platforms: What Transfers And What Breaks")
RNA Platforms: What Transfers And What BreaksA practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.
-
![vaccine, vaccination, virus dna doubts questions-GettyImages-1308261360]( "The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of Therapeutics")
The Hidden Language Of RNA: How lncRNA-Splicing Networks Are Redefining The Future Of TherapeuticsLong non-coding RNAs and splicing networks are emerging as master regulators of cellular identity, opening new therapeutic opportunities beyond proteins.
-
![Ribosome as part of an biological cell constructing mRNA molecule-GettyImages-1352440312]( "RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease Biology")
RNA-Binding Proteins As Architects Of Post-Transcriptional Control In Disease BiologyRNA-binding proteins orchestrate splicing, stability, localization, and translation, emerging as powerful regulators and therapeutic targets in disease.
-
![Emergency medicine-GettyImages-2055655561]( "Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In Cardiology")
Targeting The Uncharted Heart: Why The Next Era Of siRNA Belongs In CardiologyDuring our conversation, Gallagher walked me through what’s keeping her up at night as she leads the company and its first siRNA candidate toward an IND, elaborating on the role RNA can play in cardiomyopathies and identifying the unique challenges of developing RNA medicines today.
-
![molecular scissors, manipulation of molecular biology, RNA molecule-GettyImages-2213997299]( "Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics")
Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi TherapeuticsAs siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.
FORMULATION VIDEOS
Unlock seamless transition from lab-scale nanoparticle research to commercial production. Learn how scalable turbulent-jet mixing ensures precise, uniform, and reproducible formulation results.
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
Discover the unparalleled flexibility and automation that sets the IJM NanoScaler Pro apart from other lipid nanoparticle systems.
It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1264101698-lab-research-scientist]( "Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications")
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
-
![mRNA GettyImages-1356994723]( "The Future Of mRNA: Four Key Focuses For Industry")
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
![GettyImages-1392303980-chromatography-LC]( "Analysis Of LNP Lipids With Evaporative Light Scattering Detection")
Jump into this thorough analysis of lipids in LNP formulations using HPLC, a technique crucial for quality control in the production of mRNA vaccines and therapeutics.
-
![Lipid Nanoparticles GettyImages-1437855772]( "Rethink Cell Therapy With LNPs")
Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.
-
![GettyImages-1194781834-cell]( "mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations")
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
-
![GettyImages-2213035533 microscope, lab]( "The Importance Of Linear Scalability In Nanoparticle Processing")
Learn how turbulent jet mixing enables linear scalability, guaranteeing consistent nanoparticle quality from research to commercial production and accelerating product timelines.
-
![GettyImages-1269045566-rna]( "Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges")
Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain. However, the right mixing could solve three of these key challenges regarding instrumentation.
